Stock listing

NASDAQ:GRI GRI Bio, Inc. Stock

Home listing (NASDAQ) of GRI Bio, Inc.

Follow GRI Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:GRI

$1.12 USD -0.15 (-11.8%)

Close on Nov 20, 2026

Past year -98.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.12 – $1.25 USDNov 20, 2026
Volume
25,075 sharesNov 20, 2026
Market cap
$2.45M USDAt the close on Nov 20, 2026 · price × 2.19M shares outstanding
52-week range
$1.12 – $64.12 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$526,803 USDMedian day 48,379 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
GRI Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GRI · Home$1.12 USD-0.15 (-11.8%)25,075$1.25$1.25$1.12$1.27Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GRI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.12-0.15-11.8%$1.25$1.25$1.1225,075
$1.27-0.08-5.9%$1.303$1.329$1.2526,577
$1.35-0.05-3.5%$1.445$1.45$1.3324,265
$1.40-0.30-17.6%$1.63$1.63$1.38115,586
$1.70-0.12-6.6%$1.79$1.83$1.7021,792
$1.82-0.01-0.5%$1.73$1.88$1.7248,019
$1.83-0.06-3.2%$1.896$1.971$1.7256,057
$1.89+0.18+10.5%$1.85$1.91$1.7557,248
$1.71-0.17-9.0%$1.84$1.872$1.7137,457
$1.88+0.33+21.3%$1.56$1.94$1.5643,234
$1.55+0.12+8.4%$1.47$1.67$1.47128,793
$1.43-0.11-7.1%$1.53$1.54$1.3648,379
$1.54+0.08+5.5%$1.47$1.552$1.4252,114
$1.46-0.07-4.6%$1.529$1.56$1.4612,122
$1.53-0.04-2.5%$1.59$1.59$1.4528,212
$1.57-0.055-3.4%$1.60$1.65$1.5721,991
$1.625+0.045+2.8%$1.57$1.66$1.576,260
$1.58+0.08+5.3%$1.51$1.629$1.48733,197
$1.50+0.05+3.4%$1.47$1.52$1.4411,644
$1.45+0.03+2.1%$1.45$1.53$1.42264,900
$1.42-0.05-3.4%$1.46$1.47$1.385102,300
$1.47+0.01+0.7%$1.58$1.58$1.4659,000
$1.46+0.01+0.7%$1.45$1.538$1.4546,700
$1.45+0.07+5.1%$1.37$1.50$1.3642,600
$1.38-0.02-1.4%$1.485$1.56$1.3744,300
$1.400.000.0%$1.43$1.45$1.3828,500
$1.40-0.15-9.7%$1.54$1.56$1.4050,500
$1.55-0.02-1.3%$1.60$1.60$1.5228,900
$1.57-0.17-9.8%$1.75$1.75$1.5564,500
$1.74+0.06+3.6%$1.71$1.76$1.7021,300
$1.68-0.17-9.2%$1.85$1.88$1.6854,500
$1.85-0.05-2.6%$1.88$1.92$1.8531,500
$1.90-0.01-0.5%$1.91$1.975$1.8818,200
$1.91-0.05-2.6%$2.04$2.04$1.8884,600
$1.960.000.0%$2.00$2.02$1.9538,400
$1.96+0.03+1.6%$1.93$1.97$1.9120,300
$1.93-0.07-3.5%$2.05$2.05$1.9235,400
$2.00-0.10-4.8%$2.09$2.106$2.0025,600
$2.10+0.05+2.4%$2.07$2.25$2.00118,100
$2.05-0.04-1.9%$2.07$2.08$1.9553,300
$2.09-0.06-2.8%$2.13$2.18$2.02531,000
$2.15+0.10+4.9%$2.05$2.19$1.95143,400
$2.05+0.11+5.7%$1.96$2.06$1.93106,500
$1.94+0.01+0.5%$2.00$2.19$1.85260,800
$1.93+0.09+4.9%$1.86$1.96$1.77113,400
$1.84+0.03+1.7%$1.77$1.91$1.72174,200
$1.81-0.01-0.5%$1.81$1.85$1.7547,100
$1.82-0.07-3.7%$1.89$1.89$1.8069,300
$1.89-0.01-0.5%$1.86$1.97$1.86103,500
$1.90-0.04-2.1%$1.99$2.05$1.85131,700
$1.94+0.14+7.8%$1.79$2.00$1.78213,600
$1.80-0.20-10.0%$1.97$1.97$1.76199,500
$2.00-0.88-30.6%$2.61$2.67$1.90727,800
$2.88+0.59+25.8%$2.34$3.36$2.337,464,800
$2.29+0.29+14.5%$2.08$2.50$2.011,599,900
$2.00+0.09+4.7%$1.92$2.02$1.8785,800
$1.91-0.01-0.5%$1.90$1.98$1.8440,300
$1.920.000.0%$1.93$1.97$1.8643,000
$1.92-0.15-7.2%$2.05$2.07$1.9133,500
$2.07+0.16+8.4%$1.821$2.10$1.82178,500
$1.91-0.05-2.6%$1.96$1.96$1.8344,200
$1.96+0.17+9.5%$1.80$1.98$1.785126,500
$1.79+0.14+8.5%$1.80$1.94$1.759264,300
$1.65-0.02-1.2%$1.71$1.73$1.6583,100
$1.67-0.06-3.5%$1.73$1.77$1.66427,500

Splits

5 splits since 2023 · NASDAQ:GRI · every price before a split is adjusted for it

DayRatioWhat
1-for-28Consolidation
1-for-17Consolidation
1-for-13Consolidation
1-for-7Consolidation
1-for-30Consolidation
Ticker
NASDAQ:GRI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All GRI Bio, Inc. news

GRI Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 48 in all · newest Sep 28, 2026 · oldest 2021
Decks
8 decks · latest Sep 8, 2026

Where GRI Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GRI · Home listing · This pageNASDAQUnited StatesUSD
BOATS:GRIBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 0.5×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$6.99M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
BioAtla, Inc. · NASDAQ:BCABUS$2.58MUS$2.01Mn/an/an/an/an/an/a-0.34
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Median of the othersUS$2.40MUS$2.10M0.7×20.1×0.5×−63.4%0.1×1.19

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
18.50 USD · Analysts' mean
EPS, year to Dec 2026
-3.90 · 2 analysts

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−17.6%
Q2 2026Aug 14, 2026 · Before open−5.7%
Q1 2026May 13, 2026 · After close−4.9%
Q4 2025Jan 30, 2026 · Before open−1.8%
Q3 2025Nov 14, 2025 · Before open0.0%
Q2 2025Aug 14, 2025 · Before open+10.8%
Q1 2025May 15, 2025 · Before open−1.4%
Q4 2024Mar 26, 2025 · After close−1.3%
Q3 2024Nov 14, 2024 · After close−19.6%
Q2 2024Aug 14, 2024 · Before open−7.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open−0.5%
Q4 2023Feb 22, 2024 · Before open−12.0%
Q3 2023Nov 14, 2023 · After close−6.5%
Q2 2023Aug 8, 2023−19.7%
Q1 2023May 10, 2023−3.3%
Q4 2022Feb 23, 20230.0%
Q3 2022Nov 3, 2022−3.1%
Q2 2022Jul 28, 2022−7.6%
Q1 2022May 9, 20220.0%
Q4 2021Feb 14, 20220.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck21 slidesSep 8, 2026
Investor Presentation (August 2025)Investor deck23 slidesAug 20, 2025
Investor Presentation (August 2024)Investor deck25 slidesAug 14, 2024
Investor Presentation (May 2024)Investor deck25 slidesMay 13, 2024
Investor Presentation (January 2024)Investor deck28 slidesJan 16, 2024
Investor Presentation (August 2023)Investor deck28 slidesAug 25, 2023
Investor Presentation (April 2023)Investor deck22 slidesApr 27, 2023
Vallon Pharmaceuticals — Merger or Acquisition (December 2022)Merger or acquisition24 slidesDec 13, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock (or common stock equivalents) and Series F warrants
Closed: US$8M raised · US$0.75 a share · Warrants at US$0.75 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product candidate development, working capital and general corporate purposes
Dec 12, 2025
Public offering of shares of common stock (or common stock equivalents) and accompanying Series E-1, E-2 and E-3 warrants
Closed: US$5M raised · US$3.6 a share · Warrants at US$3.2 · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Product candidate development, working capital and general corporate purposes
Apr 2, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Vallon Pharmaceuticals, Inc. Priced at US$8.00 a share on Feb 9, 2021.

Price
US$8.00 a share
Shares offered
2,250,000 shares of common stock
Offering size
US$18 million
Underwriters' option
Up to 337,500 more shares
Listing
VLON on the Nasdaq Capital Market
Underwriter
ThinkEquity
Shares delivered
On or about Feb 12, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceSep 11, 2020
Filed publiclyOct 23, 2020
Amended 3 timesNewest Jan 28, 2021
Shares registered with an exchangeFeb 8, 2021
Declared effective by the SECFeb 9, 2021
Final prospectus, with the priceFeb 11, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 11, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue022.5M21.8M00100.0K
Cost of revenue4.00K4.00K57.0K50.0K73.0K100.0K735612
Gross profit-4.00K-4.00K-57.0K-50.0K-73.0K100.0K-735-612
Research and development6.82M3.77M3.23M242.0K5.19M3.71M1.88M3.51M
Selling, general and administrative5.16M4.47M8.15M2.00M813.0K1.20M
Operating income-12.0M-8.23M-11.4M-2.24M-9.26M-4.79M-3.15M-4.31M
Depreciation and amortization4.00K4.00K4.00K3.00K73.0K75.0K735612
EBITDA-12.0M-8.23M-11.4M-2.24M-9.19M-4.71M-3.15M-4.31M
Interest expense6.00K2.08M653.0K547.0K34.0K197.0K
Income before tax-12.0M-8.21M-13.0M-3.22M-1.56M-2.53M-3.46M-4.31M
Income tax3.00K2.00K2.77M325.0K-50.0K-131.3K5-2
Net income-12.0M-8.21M-13.0M-3.22M-9.30M-4.82M-3.46M-4.31M
Earnings per share, basic-121.80-1,545.55-5,018.09-24.95-1.42-1.07
Earnings per share, diluted-121.80-1,545.55-5,018.09-24.95-1.42-1.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents8.23M5.03M1.81M9.00K3.70M109.0K3.82M612.7K
Short-term investments03.81M0
Current assets8.59M5.62M2.93M312.0K8.13M674.0K3.92M637.6K
Property, plant and equipment3.00K4.00K8.00K4.00K02.00K
Total assets8.67M5.74M2.96M383.0K8.34M955.0K4.28M639.2K
Accounts payable1.84M897.0K1.41M1.29M918.0K1.23M246.3K286.6K
Current liabilities2.64M1.64M2.70M1.99M2.44M2.23M807.5K486.3K
Total debt71.0K119.0K14.0K673.0K3.61M336.0K340.0K
Total liabilities2.66M1.71M2.70M2.01M2.52M2.41M1.06M486.3K
Shareholders' equity6.01M4.03M259.0K-1.63M-4.85M-1.45M3.21M152.9K
Shares outstanding497.7K18.8K2.91K142.8K6.81M4.51M891891

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-10.2M-8.61M-8.99M-1.08M-8.31M-3.71M-2.88M-2.37M
Capital spending-3.00K0-8.00K-3.00K0-2.00K-5-2.21K
Free cash flow-10.2M-8.61M-9.00M-1.09M-8.31M-3.71M-2.88M-2.37M
Cash from investing-3.00K0-8.00K-3.00K-3.84M-2.00K-2.20K
Cash from financing13.4M11.8M10.8M1.01M15.7M-4.00K6.09M2.99M
Dividends paid-2.92M-3.45M
Share buybacks-1.00K-1.00K0-124.0K0
Change in cash3.20M3.22M1.80M-81.0K3.59M-3.71M3.21M612.7K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansNov 13, 2026Offer documentSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
8-K · Current reportNov 4, 2026Management or board changeSEC
ARS · Annual report to shareholdersSep 28, 2026Annual reportSEC
DEF 14A · Proxy statementSep 28, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 8, 2026Current reportSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportJun 18, 2026Current reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
8-K · Current reportFeb 4, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2026Other filingsSEC
CORRESP · Letter to the SECJan 30, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 30, 2026Other filingsSEC
10-K · Annual reportJan 30, 2026Annual reportSEC
8-K · Current reportJan 29, 2026Material contractSEC
424B5 · ProspectusJan 29, 2026Offer documentSEC
S-3 · Registration statementJan 29, 2026Offer documentSEC
S-8 · Registration statement for employee plansJan 29, 2026Offer documentSEC
8-K · Current reportJan 28, 2026Current reportSEC
8-K · Current reportJan 21, 2026Current reportSEC
8-K · Current reportJan 16, 2026Current reportSEC
8-K · Current reportJan 15, 2026Meeting outcomeSEC
8-K · Current reportJan 9, 2026Current reportSEC
424B5 · ProspectusJan 9, 2026Offer documentSEC
8-K · Current reportJan 8, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 29, 2025Big-stake noticeSEC
DEF 14A · Proxy statementDec 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementDec 19, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2025Big-stake noticeSEC
8-K · Current reportDec 12, 2025Current reportSEC
424B4 · ProspectusDec 12, 2025Offer documentSEC
8-K · Current reportDec 12, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveDec 12, 2025Other filingsSEC
8-K · Current reportDec 10, 2025Current reportSEC
CORRESP · Letter to the SECDec 9, 2025Other filingsSEC
CORRESP · Letter to the SECDec 9, 2025Other filingsSEC
S-1/A · Registration statement, amendedDec 9, 2025Offer documentSEC
S-1 · Registration statementDec 8, 2025Offer documentSEC
424B3 · ProspectusDec 8, 2025Offer documentSEC
8-K · Current reportDec 8, 2025Current reportSEC
8-K · Current reportDec 2, 2025Current reportSEC
424B3 · ProspectusNov 14, 2025Offer documentSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
UPLOAD · Letter from the SECAug 22, 2025Other filingsSEC
8-K · Current reportAug 20, 2025Current reportSEC
DRSLTR · Letter to the SEC with a draftAug 15, 2025Other filingsSEC
DRS · Draft registration statementAug 15, 2025Offer documentSEC
424B3 · ProspectusAug 15, 2025Offer documentSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
S-8 · Registration statement for employee plansAug 13, 2025Offer documentSEC
8-K · Current reportAug 13, 2025Management or board changeSEC
8-K · Current reportJul 31, 2025Current reportSEC
ARS · Annual report to shareholdersJul 11, 2025Annual reportSEC
DEF 14A · Proxy statementJul 11, 2025Meeting noticeSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportMay 23, 2025Current reportSEC
424B5 · ProspectusMay 23, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportMay 5, 2025Current reportSEC
424B5 · ProspectusMay 5, 2025Offer documentSEC
8-K · Current reportApr 15, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2025Big-stake noticeSEC
424B4 · ProspectusApr 2, 2025Offer documentSEC
8-K · Current reportApr 2, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveApr 2, 2025Other filingsSEC
CORRESP · Letter to the SECMar 26, 2025Other filingsSEC
CORRESP · Letter to the SECMar 26, 2025Other filingsSEC
S-1/A · Registration statement, amendedMar 26, 2025Offer documentSEC
S-1 · Registration statementMar 25, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 18, 2025Other filingsSEC
8-K · Current reportMar 17, 2025ResultsSEC
DRS · Draft registration statementMar 14, 2025Offer documentSEC
10-K · Annual reportMar 14, 2025Annual reportSEC
8-K · Current reportMar 11, 2025Current reportSEC
8-K · Current reportFeb 19, 2025Current reportSEC
8-K · Current reportFeb 11, 2025Meeting outcomeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
DEF 14A · Proxy statementJan 17, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementJan 7, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansJan 6, 2025Offer documentSEC
8-K · Current reportDec 20, 2024Current reportSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 25, 2024Other filingsSEC
CORRESP · Letter to the SECNov 20, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 20, 2024Other filingsSEC
424B3 · ProspectusNov 15, 2024Offer documentSEC
S-3 · Registration statementNov 14, 2024Offer documentSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
DOct 25, 2024Other filingsSEC
8-K · Current reportOct 24, 2024Current reportSEC
8-K · Current reportOct 22, 2024Material contractSEC
8-K/A · Current report, amendedSep 11, 2024Current reportSEC
424B3 · ProspectusSep 10, 2024Offer documentSEC
424B3 · ProspectusSep 10, 2024Offer documentSEC
8-K · Current reportSep 10, 2024Current reportSEC
8-K · Current reportSep 6, 2024Meeting outcomeSEC
424B3 · ProspectusAug 28, 2024Offer documentSEC
424B3 · ProspectusAug 28, 2024Offer documentSEC
424B3 · ProspectusAug 28, 2024Offer documentSEC
DEFA14A · Additional proxy materialAug 23, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialAug 23, 2024Meeting noticeSEC
8-K · Current reportAug 23, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialAug 16, 2024Meeting noticeSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
ARS · Annual report to shareholdersAug 2, 2024Annual reportSEC
DEF 14A · Proxy statementAug 2, 2024Meeting noticeSEC
8-K · Current reportJul 26, 2024Current reportSEC
424B5 · ProspectusJul 26, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementJul 23, 2024Meeting noticeSEC
8-K · Current reportJul 19, 2024Current reportSEC
424B5 · ProspectusJul 19, 2024Offer documentSEC
8-K · Current reportJul 8, 2024Current reportSEC
424B4 · ProspectusJun 27, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveJun 27, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 26, 2024Offer documentSEC
CORRESP · Letter to the SECJun 25, 2024Other filingsSEC
CORRESP · Letter to the SECJun 25, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 25, 2024Offer documentSEC
UPLOAD · Letter from the SECJun 24, 2024Other filingsSEC
S-1 · Registration statementJun 18, 2024Offer documentSEC
424B3 · ProspectusJun 18, 2024Offer documentSEC
424B3 · ProspectusJun 18, 2024Offer documentSEC
8-K · Current reportJun 18, 2024Management or board changeSEC
424B3 · ProspectusJun 14, 2024Offer documentSEC
424B3 · ProspectusJun 14, 2024Offer documentSEC
8-K · Current reportJun 14, 2024Current reportSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
424B3 · ProspectusMay 31, 2024Offer documentSEC
424B3 · ProspectusMay 31, 2024Offer documentSEC
8-K · Current reportMay 22, 2024Current reportSEC
424B3 · ProspectusMay 20, 2024Offer documentSEC
424B3 · ProspectusMay 20, 2024Offer documentSEC
8-K · Current reportMay 20, 2024Material contractSEC
424B5 · ProspectusMay 20, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 17, 2024Other filingsSEC
424B3 · ProspectusMay 14, 2024Offer documentSEC
424B3 · ProspectusMay 14, 2024Offer documentSEC
CORRESP · Letter to the SECMay 14, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
8-K · Current reportMay 13, 2024ResultsSEC
S-3 · Registration statementMay 10, 2024Offer documentSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
DEF 14A · Proxy statementMay 9, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportApr 1, 2024ResultsSEC
424B3 · ProspectusMar 28, 2024Offer documentSEC
424B3 · ProspectusMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
424B3 · ProspectusFeb 2, 2024Offer documentSEC
8-K · Current reportFeb 2, 2024Material contractSEC
424B4 · ProspectusFeb 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 2, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 31, 2024Offer documentSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 30, 2024Offer documentSEC
424B3 · ProspectusJan 30, 2024Offer documentSEC
8-K · Current reportJan 30, 2024Current reportSEC
424B3 · ProspectusJan 19, 2024Offer documentSEC
8-K · Current reportJan 19, 2024Meeting outcomeSEC
8-K · Current reportJan 16, 2024Current reportSEC

This page holds 200 of 409 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from GRI Bio, Inc.’s releases · as of Nov 12, 2026

Common shares
2,186,115
Fully diluted
2,186,115

Fully diluted

LineSharesAs of
Common shares2,186,115Nov 12, 2026

Warrants and options

Lot
Warrants · US$0.75 · expire about Dec 2030
Warrants · US$3.20 · expiry not stated

Share count over time

CountShares
Nov 12, 20262,186,115

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Jane Street30,7211.4%US$59,291Sep 30, 2026
Hrt Financial LP26,4021.2%US$50,000Sep 30, 2026
Vanguard21,3680.98%US$41,240Sep 30, 2026
UBS19,0290.87%US$36,726Sep 30, 2026
Geode Capital10,0450.46%US$19,386Sep 30, 2026
Morgan Stanley8,7370.40%US$16,862Sep 30, 2026
Citigroup Inc1,6450.08%US$3,175Sep 30, 2026
Tower Research Capital LLC (TRC)7310.03%US$1,411Sep 30, 2026
BlackRock7<0.01%US$14Sep 30, 2026
Caitong International Asset Management Co., Ltd3<0.01%US$6Sep 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
Robinhood Markets, Inc.2<0.01%US$4Sep 30, 2026
Danske Bank A/S2<0.01%US$4Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund21,3680.98%US$37,821Jun 30, 2026
Fidelity Extended Market Index Fund13,7070.63%US$28,922May 31, 2026
Fidelity Series Total Market Index Fund8720.04%US$1,840May 31, 2026

Big stakes

StakeStakeSharesDateFiling
MJL Manager LLC7.30%159KNov 5, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Marella Thorell
Other companies: Carisma Therapeutics, Inc. (Director · Since at least Jun 30, 2024); Seres Therapeutics, Inc. (EVP, Chief Financial Officer · Since at least Mar 25, 2024); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Evelo Biosciences, Inc. (Chief Financial Officer · Jul 13, 2022 – Nov 7, 2023 · Past); Centessa Pharmaceuticals PLC (Chief Accounting Officer · May 27, 2021 – Mar 21, 2022 · Past)
Director · Feb 9, 2021 – Dec 13, 2022 · Past
David Szekeres
Other companies: Connect Biopharma Holdings Limited (PRESIDENT · Since at least Mar 31, 2025); Heron Therapeutics, Inc. (EVP, Chief Operating Officer · Oct 13, 2020 – Jul 13, 2023 · Past); Regulus Therapeutics Inc (Chief Business Officer & GC · Mar 10, 2014 – Dec 2, 2014 · Past)
Director · Since at least Apr 21, 2023
Camilla V. Simpson
Other companies: Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020)
Director · Since at least Apr 21, 2023
Joe Payne
Other companies: Arcturus Therapeutics Holdings Inc. (President and CEO, Director · Since at least Jan 1, 2019)
Director · Feb 9, 2021 – Jun 9, 2022 · Past
Leanne KellyChief Financial Officer · Since at least Aug 26, 2025
Penny TorenSVP, Regul Affairs & Prog Mgmt · Feb 9, 2021 – May 14, 2021 · Past
Roelof RongenDirector · Since at least Apr 21, 2023
Vipin ChaturvediChief Scientific Officer · Since at least Apr 21, 2023
Walter Marc HertzChief Executive Officer, Director · Since at least Apr 21, 2023

Open People

Log in to ask 6ix AI your own questions about GRI Bio, Inc.